FDA Adds RA Indication for Riabni Rituximab Biosimilar FDA Adds RA Indication for Riabni Rituximab Biosimilar
Riabni is the second rituximab biosimilar to be approved for rheumatoid arthritis in the United States.FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news
More News: Arthritis | Drugs & Pharmacology | Rheumatoid Arthritis | Rheumatology | Rituxan | USA Health